Alivus Life Sciences Limited · ALIVUS
Every Alivus Life Sciences Limited result whose ten-session window has closed, judged against the last read made before it. Open a result for the full account: the read, the sessions after, the reported figures, and every morning's read that led up to it. The company's own page →
7results judged
0read right
0read wrong
0flat / no call
7unread
43%beat the market
+2.6%avg vs market, 10d
3.9%avg move, T+1
How the reads on it fared
| Read | Judged | Right | Wrong | Flat | Hit rate | Avg vs mkt | |
|---|---|---|---|---|---|---|---|
| unread | 7 | 0 | 0 | 0 | — | +2.6% |
A company that is often read strong and often proves it is one the model understands; one that is read strong and keeps lagging is where the model is wrong about a name, and this table is where that shows first.
Reading the rows
- T+1
- the share's move on the first session after the result, from the close before it
- T+10
- the move over ten sessions, same base
- vs market
- T+10 less NIFTY 50's move over the same ten sessions — the number every read is judged on
- Run-up
- the share's move in the thirty sessions before the result
- Result
- reported profit growth against the company's own last four quarters: good, in line, bad
Each result
7 judged · newest first · open one| Result | Read | Outcome | T+1 | T+10 | vs market | Run-up | Result | Why | |
|---|---|---|---|---|---|---|---|---|---|
| 30 Jul Q1FY27 | — | unread | +10.8% | +26.6% | +26.4% | +3% | no figures |
|
› |
| 14 May Q4FY26 | — | unread | -0.8% | -0.8% | -0.2% | +9% | no figures |
|
› |
| 22 Jan Q3FY26 | — | unread | +3.1% | +8.9% | +6.6% | -4% | no figures |
|
› |
| 6 Nov Q2FY26 | — | unread | +3.4% | +1.5% | -0.7% | -11% | no figures |
|
› |
| 1 Aug Q1FY26 | — | unread | -1.4% | -3.3% | -5.0% | +0% | no figures |
|
› |
| 15 May Q4FY25 | — | unread | -5.1% | -13.7% | -12.4% | +14% | no figures |
|
› |
| 23 Jan Q3FY25 | — | unread | +2.6% | +4.9% | +3.4% | — | no figures |
|
› |